Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers

Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53...

Full description

Bibliographic Details
Main Authors: Dodbiba, Lorin, Teichman, Jennifer, Fleet, Andrew, Thai, Henry, Starmans, Maud H. W., Navab, Roya, Chen, Zhuo, Girgis, Hala, Eng, Lawson, Espin-Garcia, Osvaldo, Shen, Xiaowei, Bandarchi, Bizhan, Schwock, Joerg, Tsao, Ming-Sound, El-Zimaity, Hala, Der, Sandy D., Xu, Wei, Bristow, Robert G., Darling, Gail E., Boutros, Paul C., Ailles, Laurie E., Liu, Geoffrey
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380353/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380353/

Similar Items